港股荣昌生物今日盘中大涨7.61%,引发市场广泛关注。股价大涨主要受以下因素影响:
首先,该公司公布的2024年年度业绩预告显示,虽然依然亏损,但营业收入同比增长约58%,净亏损额同比减少约3%,呈减亏趋势,表现良好。公司新药研发管线持续推进,多款创新药品处于关键试验阶段,也拉动收入增长。
其次,荣昌生物今年将迎来多个新药获批及递交上市申请的重要进展,包括泰它西普治疗重症肌无力的获批,维迪西妥单抗乳腺癌及尿路上皮癌适应症上市申请等。这将推动公司业务增长,增强市场对其长远发展前景的信心。
综上所述,公司去年业绩表现令人鼓舞,且新药临床进展顺利,这些利好因素均助推股价今日大涨。分析人士认为,只要荣昌生物保持较快增长势头,未来两到三年有望实现扭亏为盈。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.